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SUPPLEMENTARY DATA 
 
Supplemental Table 1: List of 203 genes encoding proteins containing FN3-domains (Prosite 
database, PS50835, index in 09 Feb. 2017)  
Entry  Gene  Protein names 
Q8N957  ANKF1  Ankyrin repeat and fibronectin type-III domain-containing protein 1 
O75129  ASTN2  Astrotactin-2 
Q9BWV1  BOC  Brother of CDO (Protein BOC) 
Q4KMG0  CDON  Cell adhesion molecule-related/down-regulated by oncogenes 
Q8N3K9  CMYA5  Cardiomyopathy-associated protein 5 
P26992  CNTFR  Ciliary neurotrophic factor receptor subunit alpha 
Q12860  CNTN1  Contactin-1 
Q02246  CNTN2  Contactin-2 
Q9P232  CNTN3  Contactin-3 
Q8IWV2  CNTN4  Contactin-4 
O94779  CNTN5  Contactin-5 
Q9UQ52  CNTN6  Contactin-6 
P12111  CO6A3  Collagen alpha-3(VI) chain 
Q02388  CO7A1  Collagen alpha-1(VII) chain 
Q99715  COCA1  Collagen alpha-1(XII) chain 
Q05707  COEA1  Collagen alpha-1(XIV) chain 
Q9P218  COKA1  Collagen alpha-1(XX) chain 
O75462  CRLF1  Cytokine receptor-like factor 1 
Q9HC73  CRLF2  Cytokine receptor-like factor 2 
Q8IUI8  CRLF3  Cytokine receptor-like factor 3 
P15509  CSF2R  Granulocyte-macrophage colony-stimulating factor receptor subunit alpha 
Q99062  CSF3R  Granulocyte colony-stimulating factor receptor 
P43146  DCC  Netrin receptor DCC 
O60469  DSCAM  Down syndrome cell adhesion molecule 
Q8TD84  DSCL1  Down syndrome cell adhesion molecule-like protein 1 
Q63HQ2  EGFLA  Pikachurin 
P0C7U0  ELFN1  Protein ELFN1 
P21709  EPHA1  Ephrin type-A receptor 1 
P29317  EPHA2  Ephrin type-A receptor 2 
P29320  EPHA3  Ephrin type-A receptor 3 
P54764  EPHA4  Ephrin type-A receptor 4 
P54756  EPHA5  Ephrin type-A receptor 5 
Q9UF33  EPHA6  Ephrin type-A receptor 6 
Q15375  EPHA7  Ephrin type-A receptor 7 
P29322  EPHA8  Ephrin type-A receptor 8 
Q5JZY3  EPHAA  Ephrin type-A receptor 10 
P54762  EPHB1  Ephrin type-B receptor 1 
P29323  EPHB2  Ephrin type-B receptor 2 
P54753  EPHB3  Ephrin type-B receptor 3 
P54760  EPHB4  Ephrin type-B receptor 4 
O15197  EPHB6  Ephrin type-B receptor 6 
P19235  EPOR  Erythropoietin receptor 
Q8TC84  FANK1  Fibronectin type 3 and ankyrin repeat domains protein 1 
P02751  FINC  Fibronectin 
Q9NZU1  FLRT1  Leucine-rich repeat transmembrane protein FLRT1 
O43155  FLRT2  Leucine-rich repeat transmembrane protein FLRT2 
Q9NZU0  FLRT3  Leucine-rich repeat transmembrane protein FLRT3 
F2Z333  FND10  Fibronectin type III domain-containing protein 10 
Q9BVV2  FND11  Fibronectin type III domain-containing protein 11 
Q9Y2H6  FND3A  Fibronectin type-III domain-containing protein 3A 
Q53EP0  FND3B  Fibronectin type III domain-containing protein 3B 
Q4ZHG4  FNDC1  Fibronectin type III domain-containing protein 1 
Q9H6D8  FNDC4  Fibronectin type III domain-containing protein 4 
Q8NAU1  FNDC5  Fibronectin type III domain-containing protein 5 
Q5VTL7  FNDC7  Fibronectin type III domain-containing protein 7 
Q8TC99  FNDC8  Fibronectin type III domain-containing protein 8 
Q8TBE3  FNDC9  Fibronectin type III domain-containing protein 9 
Q9BTV5  FSD1  Fibronectin type III and SPRY domain-containing protein 1 
Q9BXM9  FSD1L  FSD1-like protein 
A1L4K1  FSD2  Fibronectin type III and SPRY domain-containing protein 2 
P10912  GHR  Growth hormone receptor 
P51610  HCFC1  Host cell factor 1 (HCF) 
Q9Y5Z7  HCFC2  Host cell factor 2 
Q08334  I10R2  Interleukin-10 receptor subunit beta 
Q14626  I11RA  Interleukin-11 receptor subunit alpha 
P42701  I12R1  Interleukin-12 receptor subunit beta-1 
Q99665  I12R2  Interleukin-12 receptor subunit beta-2 
P78552  I13R1  Interleukin-13 receptor subunit alpha-1 
Q14627  I13R2  Interleukin-13 receptor subunit alpha-2 
Q9UHF4  I20RA  Interleukin-20 receptor subunit alpha 
Q6UXL0  I20RB  Interleukin-20 receptor subunit beta 
Q8N6P7  I22R1  Interleukin-22 receptor subunit alpha-1 
Q969J5  I22R2  Interleukin-22 receptor subunit alpha-2 
Q6UWB1  I27RA  Interleukin-27 receptor subunit alpha 
Q8IVU1  IGDC3  Immunoglobulin superfamily DCC subclass member 3 
Q8TDY8  IGDC4  Immunoglobulin superfamily DCC subclass member 4 
P08069  IGF1R  Insulin-like growth factor 1 receptor 
Q86VF2  IGFN1  Immunoglobulin-like and fibronectin type III domain-containing protein 1 
Q8N9C0  IGS22  Immunoglobulin superfamily member 22 
P29460  IL12B  Interleukin-12 subunit beta 
Q9HBE5  IL21R  Interleukin-21 receptor 
Q5VWK5  IL23R  Interleukin-23 receptor 
Q14213  IL27B  Interleukin-27 subunit beta 
P14784  IL2RB  Interleukin-2 receptor subunit beta 
P31785  IL2RG  Cytokine receptor common subunit gamma 
Q8NI17  IL31R  Interleukin-31 receptor subunit alpha 
P32927  IL3RB  Cytokine receptor common subunit beta 
P24394  IL4RA  Interleukin-4 receptor subunit alpha 
Q01344  IL5RA  Interleukin-5 receptor subunit alpha 
P08887  IL6RA  Interleukin-6 receptor subunit alpha 
P40189  IL6RB  Interleukin-6 receptor subunit beta 
P16871  IL7RA  Interleukin-7 receptor subunit alpha 
Q01113  IL9R  Interleukin-9 receptor 
P17181  INAR1  Interferon alpha/beta receptor 1 
P15260  INGR1  Interferon gamma receptor 1 
P38484  INGR2  Interferon gamma receptor 2 
Q8IU57  INLR1  Interferon lambda receptor 1 
P06213  INSR  Insulin receptor 
P14616  INSRR  Insulin receptor-related protein 
P16144  ITB4  Integrin beta-4 
P23352  KALM  Anosmin-1 
O60229  KALRN  Kalirin 
P32004  L1CAM  Neural cell adhesion molecule L1 
P48357  LEPR  Leptin receptor 
P42702  LIFR  Leukemia inhibitory factor receptor 
Q9P244  LRFN1  Leucine-rich repeat and fibronectin type III domain-containing protein 1 
Q9ULH4  LRFN2  Leucine-rich repeat and fibronectin type-III domain-containing protein 2 
Q9BTN0  LRFN3  Leucine-rich repeat and fibronectin type-III domain-containing protein 3 
Q6PJG9  LRFN4  Leucine-rich repeat and fibronectin type-III domain-containing protein 4 
Q96NI6  LRFN5  Leucine-rich repeat and fibronectin type-III domain-containing protein 5 
Q9P2V4  LRIT1  
Leucine-rich repeat, immunoglobulin-like domain and transmembrane 
domain-containing protein 1 
A6NDA9  LRIT2  
Leucine-rich repeat, immunoglobulin-like domain and transmembrane 
domain-containing protein 2 
Q3SXY7  LRIT3  
Leucine-rich repeat, immunoglobulin-like domain and transmembrane 
domain-containing protein 3 
Q8ND94  LRN4L  LRRN4 C-terminal-like protein 
Q6UXK5  LRRN1  Leucine-rich repeat neuronal protein 1 
Q9H3W5  LRRN3  Leucine-rich repeat neuronal protein 3 
Q8WUT4  LRRN4  Leucine-rich repeat neuronal protein 4 
A2RUH7  MBPHL  Myosin-binding protein H-like 
Q6VMQ6  MCAF1  Activating transcription factor 7-interacting protein 1 
Q5U623  MCAF2  Activating transcription factor 7-interacting protein 2 
Q8NFP4  MDGA1  MAM domain-containing glycosylphosphatidylinositol anchor protein 1 
Q7Z553  MDGA2  MAM domain-containing glycosylphosphatidylinositol anchor protein 2 
Q12866  MERTK  Tyrosine-protein kinase Mer 
Q13203  MYBPH  Myosin-binding protein H 
Q15746  MYLK  Myosin light chain kinase, smooth muscle 
P52179  MYOM1  Myomesin-1 
P54296  MYOM2  Myomesin-2 
Q5VTT5  MYOM3  Myomesin-3 
Q00872  MYPC1  Myosin-binding protein C, slow-type 
Q14324  MYPC2  Myosin-binding protein C, fast-type 
Q14896  MYPC3  Myosin-binding protein C, cardiac-type 
P13591  NCAM1  Neural cell adhesion molecule 1 
O15394  NCAM2  Neural cell adhesion molecule 2 
O00533  NCHL1  Neural cell adhesion molecule L1-like protein 
Q8TB73  NDNF  Protein NDNF 
Q92859  NEO1  Neogenin 
O94856  NFASC  Neurofascin 
O60500  NPHN  Nephrin 
Q92823  NRCAM  Neuronal cell adhesion molecule 
Q5VST9  OBSCN  Obscurin 
O75147  OBSL1  Obscurin-like protein 1 
Q99650  OSMR  Oncostatin-M-specific receptor subunit beta 
Q96FC7  PHIPL  Phytanoyl-CoA hydroxylase-interacting protein-like 
Q92561  PHYIP  Phytanoyl-CoA hydroxylase-interacting protein 
Q8NAT1  PMGT2  Protein O-linked-mannose beta-1,4-N-acetylglucosaminyltransferase 2 
Q5R3F8  PPR29  Protein phosphatase 1 regulatory subunit 29 
P16471  PRLR  Prolactin receptor 
Q2VWP7  PRTG  Protogenin 
P23467  PTPRB  Receptor-type tyrosine-protein phosphatase beta 
P08575  PTPRC  Receptor-type tyrosine-protein phosphatase C 
P23468  PTPRD  Receptor-type tyrosine-protein phosphatase delta 
P10586  PTPRF  Receptor-type tyrosine-protein phosphatase F 
P23470  PTPRG  Receptor-type tyrosine-protein phosphatase gamma 
Q9HD43  PTPRH  Receptor-type tyrosine-protein phosphatase H 
Q12913  PTPRJ  Receptor-type tyrosine-protein phosphatase eta 
Q15262  PTPRK  Receptor-type tyrosine-protein phosphatase kappa 
P28827  PTPRM  Receptor-type tyrosine-protein phosphatase mu 
Q16827  PTPRO  Receptor-type tyrosine-protein phosphatase O 
Q9UMZ3  PTPRQ  Phosphatidylinositol phosphatase PTPRQ 
Q13332  PTPRS  Receptor-type tyrosine-protein phosphatase S 
O14522  PTPRT  Receptor-type tyrosine-protein phosphatase T 
Q92729  PTPRU  Receptor-type tyrosine-protein phosphatase U 
P23471  PTPRZ  Receptor-type tyrosine-protein phosphatase zeta 
Q9UFD9  RIM3A  RIMS-binding protein 3A 
A6NNM3  RIM3B  RIMS-binding protein 3B 
A6NJZ7  RIM3C  RIMS-binding protein 3C 
O95153  RIMB1  Peripheral-type benzodiazepine receptor-associated protein 1 
O15034  RIMB2  RIMS-binding protein 2 
Q9Y6N7  ROBO1  Roundabout homolog 1 
Q9HCK4  ROBO2  Roundabout homolog 2 
Q96MS0  ROBO3  Roundabout homolog 3 
Q8WZ75  ROBO4  Roundabout homolog 4 
P08922  ROS1  Proto-oncogene tyrosine-protein kinase ROS 
Q7Z5N4  SDK1  Protein sidekick-1 
Q58EX2  SDK2  Protein sidekick-2 
Q8TER0  SNED1  Sushi, nidogen and EGF-like domain-containing protein 1 
Q92673  SORL  Sortilin-related receptor 
Q15772  SPEG  Striated muscle preferentially expressed protein kinase 
Q7Z7G0  TARSH  Target of Nesh-SH3 
P24821  TENA  Tenascin 
Q9UQP3  TENN  Tenascin-N 
Q92752  TENR  Tenascin-R 
P22105  TENX  Tenascin-X 
Q16473  TENXA  Putative tenascin-XA 
P35590  TIE1  Tyrosine-protein kinase receptor Tie-1 
Q02763  TIE2  Angiopoietin-1 receptor 
Q8WZ42  TITIN  Titin 
P40238  TPOR  Thrombopoietin receptor 
O15344  TRI18  E3 ubiquitin-protein ligase Midline-1 
Q9NQ86  TRI36  E3 ubiquitin-protein ligase TRIM36 
Q8IWZ5  TRI42  Tripartite motif-containing protein 42 
Q7Z4K8  TRI46  Tripartite motif-containing protein 46 
Q6ZTA4  TRI67  Tripartite motif-containing protein 67 
Q9UJV3  TRIM1  Probable E3 ubiquitin-protein ligase MID2 
Q9C026  TRIM9  E3 ubiquitin-protein ligase TRIM9 
Q9P2J2  TUTLA  Protein turtle homolog A 
Q9UPX0  TUTLB  Protein turtle homolog B 
Q06418  TYRO3  Tyrosine-protein kinase receptor TYRO3 
P30530  UFO  Tyrosine-protein kinase receptor UFO 
Q5DID0  UROL1  Uromodulin-like 1 
O75445  USH2A  Usherin 
Q6EMK4  VASN  Vasorin 
Q6PCB0  VWA1  von Willebrand factor A domain-containing protein 1 
 
   
Supplemental Table 2: List of 22 genes encoding proteins containing FN3-domains known to be 
involved in axon guidance (GO:0007411) 
 
 
  
Candidate 
Gene 
# rare 
variants  
# probands 
(KS/nCHH) 
ANOS1 3 3 (3/0) 
BOC 6 6 (2/4) 
CHL1 4 4 (3/1) 
CNTN2 7 12 (6/6) 
CNTN4 4 4 (3/1) 
DCC 5 7 (6/1) 
EPHA5 1 1 (1/0) 
EPHA8 3 4 (3/1) 
EPHB1 2 2 (2/0) 
EPHB2 1 3 (3/0) 
EPHB3 4 4 (3/1) 
FLRT2 3 4 (2/2) 
FLRT3 1 2 (1/1) 
L1CAM 2 2 (2/0) 
NCAM1 3 4 (0/4) 
NEO1 6 6 (4/2) 
NFASC 5 6 (4/2) 
PTPRO 3 5 (4/1) 
ROBO1 1 2 (1/1) 
ROBO2 2 5 (5/3) 
ROBO3 2 4 (1/3) 
TNR 2 2 (0/2) 
Case summaries  
 
Family # 1, Patient II-2  
DCC p.N176S (heterozygous) 
PROKR2 p.L173R (heterozygous) 
The anosmic Caucasian male was born with bilateral cryptorchidism, right inguinal hernia, micropenis 
and glandular hypospadias. Bilateral orchidopexy and right inguinal herniotomy were performed at 10 
months of age, but orchidopexies had to be repeated for right and left testes at age 7 and 9 years 
respectively. Penis size was normalized following 4 injections of Sustanon at age 2-3 years. Due to high 
risk of CHH, he continued being following by an endocrine specialist. Other phenotypes included 
delayed childhood motor milestones, delayed deciduous dentition (only 7 teeth at 2.3 years), mild 
facial asymmetry with hypoplastic right ear pinna and transverse palmar creases. Mild bilateral 
synkinesia was also observed. Renal ultrasound and head CT were normal at age 3 years. The patient 
was unable to tolerate a cranial MRI. By age 10 it became obvious that he was anosmic, which was 
confirmed later by formal testing (< 5th %ile). At age 13, he had absent puberty (testes 1 ml) and 
hormonal profiling compatible with hypogonadotropic hypogonadism (T<1.0 nmol/l, LH&FSH < 0.5 
U/l). Anterior pituitary function was otherwise normal. Based on these findings he was diagnosed with 
Kallmann syndrome and was started on testosterone treatment shortly before his 14th birthday to 
induce virilization. Hormonal assessment at age 18 confirmed the diagnosis of CHH. His parents and 
brother have normal reproductive and olfactory phenotype. The proband harbors a mutation in DCC, 
inherited by his father, as well as in PROKR2 inherited by his mother. His brother was found to also 
harbor the DCC and PROKR2 mutations. 
 
 
Family # 2, Patient II-1  
DCC p.Gly470Asp (heterozygous) 
The Caucasian male proband was born in the context of perinatal asphyxia. Physical examination 
showed micropenis without cryptorchidism, hoarse cry, moderate hypotonia and a third left nipple. 
An MRI revealed a Rathke’s cleft cyst. Gonadotropines levels were low for minipuberty (LH 0.5 U/l, FSH 
0.7 U/l) without dysfunction of other pituitary axes. An hCG-stimulation test indicated adequate 
elevation of testosterone to 14.1 nmol/l. Micropenis was corrected by 3 testosterone injections at 4 
months of age. Family history was unremarkable for puberty and reproductive status. Infancy was 
marked by retarded speech and psychomotor development. At 14 years of age, no signs of puberty 
were present. Testicular volume was 1.5 ml bilaterally. Diffuse obesity was noted with BMI of 28 kg/m2. 
Laboratory assessment confirmed hypogonadotropic hypogonadism. An MRI (under general 
anesthesia due to psychomotor agitation) revealed a reduced pituitary volume, a decrease in the size 
of the Rathke’s cyst and an asymmetry of the olfactory bulbs (absence of the right one), though both 
olfactory sulcus were visible. A formal olfactory test was impossible to perform. Induction of puberty 
by testosterone administered transcutaneously was initiated at age 15.1 years. Evaluation at 1 year of 
treatment showed satisfactory progression of virilization with a testosterone level at 5.5 nmol/l. The 
proband harbors a mutation in DCC with no changes in known CHH genes. The patient’s mother is 
carrier of the same mutation in DCC. Father’s DNA was not available. 
 
 
Family # 3, Subject III-1 
DCC p.P645S (heterozygous) 
The anosmic proband of Indian subcontinent descent was born without cryptorchidism nor micropenis 
and first presented to medical attention at age 22 years for evaluation of absent puberty despite a 
normal stature (170 cm). At that time he was unvirilized, markedly obese (BMI 40 kg/m2) and had 
prepubertal testes (3 mL). Serum measurement of reproductive hormones showed hypogonadotropic 
hypogonadism (T < 1 nmol/L, LH < 1 IU/L, FSH < 1 IU/L). Anterior pituitary function was otherwise 
normal. Anosmia was confirmed using readily-available odorants but not by quantitative smell testing. 
He returned to India before either renal ultrasound or cranial MRI could be performed. These findings 
were consistent with Kallmann syndrome and he initiated testosterone replacement therapy to induce 
virilization, but which without any change in testis volume when reassessed at age 28 years. Notably, 
both his father and paternal grandfather had delayed puberty, whereas a maternal uncle is hyposmic. 
 
Family # 4, Patient II-2 
DCC p.G649E (heterozygous) 
CHD7 p.Y1616C (heterozygous) 
SEMA3a p.R66W (heterozygous) 
The anosmic Caucasian female first presented to medical attention for evaluation of primary 
amenorrhea at age 16. Her exam was notable for lack of pubertal development and hormonal profiling 
revealed undetectable gonadotropins (LH/FSH < 1.0 U/L) in the setting of low estradiol levels (< 60 
pmol/L). Formal smell testing confirmed anosmia (UPSIT: 13/40, <5th %ile) and she was diagnosed with 
Kallmann syndrome. A renal ultrasound showed normal anatomy while a cranial MRI revealed absent 
olfactory bulbs. DEXA bone density revealed osteopenia of the hip which subsequently normalized 
with ongoing estrogen therapy. Her history is notable for mild bilateral sensorineural hearing loss 
identified on audiology testing. Her father has anosmia that is thought to be secondary to nasal polyps. 
Her brother has cerebral palsy and displayed bilateral cryptorchidism, but was biochemically 
eugonadal when tested. The patient harbors mutations in DCC, CHD7 and SEMA3a inherited by her 
mother. Her brother is also carrier of the CHD7 mutation. 
 
Family # 5, Patient II-1 
DCC p.Ser876Tyr 
The female normosmic proband of mixed origin (mother from Haiti, father from Switzerland) was 
brought to medical attention at age 17. She presented menses once at age 16, then secondary 
amenorrhea. Her physical status was notable for diffuse obesity (BMI 27.07 kg/m2), moderate facial 
acne and absent puberty (Tanner II, breast development). Laboratory data showed markedly low 
estradiol (<0.04 nmol/l) associated with undetectable gonadotropines (LH & FSH < 0.5 U/l). Polycystic 
ovaries syndrome was excluded as well as a non-classical form of congenital adrenal hyperplasia. GnRH 
stimulation testing revealed a weak FSH response (<0.4 to 1.2 U/L) and a flat LH response (< 0.5 U/l). 
No anomaly of other pituitary axes was present. Cranial MRI revealed reduced size of the pituitary 
gland with significant thinning of the distal portion of the pituitary stalk. DEXA bone density revealed 
marked osteoporosis of the lumbar spine that responded favorably to subsequent estrogen 
supplementation. Family history is characterized by delayed puberty in the mother (menarche at age 
16) with difficulty conceiving, delayed puberty in a maternal aunt (menarche at age 18) and normal 
puberty in the father. Familial heights are low at the maternal side with tendency to obesity (mother: 
85 kg, 150 cm). The patient harbors a DCC mutation without any changes in known CHH genes. 
Mother’s DNA was tested and found negative for the DCC mutation, whereas the father did not agree 
to provide blood for genetic testing.  
 
Family # 6, Patient II-1 
DCC Gly470Asp  
NTN1 Thr525Arg 
The Caucasian male proband and his brother (Patient # II-2) were born with bilateral cryptorchidism 
requiring surgical correction. He presented at age 18 for evaluation of absent pubertal development. 
He was unvirilized with prepubertal testes (< 3mL) and was noted at that time to be anosmic 
(confirmed via formal smell testing, <5th %ile). Hormone measurement revealed low gonadotropin 
levels (LH and FSH both 0.8 IU/L) in the setting of a frankly low serum testosterone (1.0 nmol/L). GnRH 
stimulation testing revealed a weak LH response (0.8 to 3.5 IU/L) and a flat FSH response (FSH remained 
0.8 IU/L). Ultrasound showed both kidneys were present and cranial MRI indicated a normal pituitary 
yet shallow olfactory sulci and intact olfactory bulbs. Based on these findings he was diagnosed with 
Kallmann syndrome and started on testosterone to induce virilization and subsequently was 
transitioned to hCG (and later pulsatile GnRH via pump) to stimulate testicular development. Besides 
his twin brother (Patient #7) there is no other family history of hypogonadism, delayed puberty or 
midline defects. The proband and his brother both harbor the same mutations in DCC and NTN1. There 
are no changes in known CHH genes.  
 
Family # 6, Patient II-2 
DCC Gly470Asp  
NTN1 Thr525Arg 
Like his twin brother (Patient #6), the Caucasian anosmic patient was born with bilateral 
cryptorchidism and underwent orchidopexy. He also presented at age 18 with absent pubertal 
development (TV < 3mL) and was confirmed to be anosmic on formal testing. His serum gonadotropins 
and testosterone levels were undetectable and he exhibited a flat response to GnRH stimulation (LH 
0.8 to 1.0 IU/L, FSH remained 0.8 IU/L). He was diagnosed with Kallmann syndrome and underwent a 
similar treatment regimen as his brother (testosterone then hCG then pulsatile GnRH). His medical 
history is also notable for pulmonary stenosis. Both brothers harbor identical mutations in DCC and 
NTN1. 
 
Family # 7, Patient II-1 
NTN1 p.Arg362Cys (heterozygous) 
GnRH p.Leu30fs (homozygous) 
The male CHH proband was first evaluated at age 8 years for bilateral cryptorchidism and micropenis 
(< 3 cm). His parents come from the same village in Armenia and deny consanguinity. Repeated 
questioning of the father revealed delayed puberty. Ultrasound identified inguinal testes with 
calculated volume of approximately 0.1 ml. Bilateral orchidopexy was performed shortly afterwards. 
At age 13 years and 6 months, there were no signs of puberty. A GnRH stimulation test showed 
undetectable baseline gonadotropines (FSH, LH < 0.5 IU/l) that responded minimally to 1.3 and 0.8 IU/l 
respectively. Formal smell testing indicated normal sense of smell. Puberty induction by testosterone 
injections was initiated and resulted in linear growth and development of secondary sexual 
characteristics. Tanner V pubic hair was seen at age 15 years and 6 months. On request of the father, 
testosterone treatment was stopped at age 16 years. The patient developed clinical and biochemical 
hypogonadism. The patient harbors a de novo mutation in NTN1. An additional homozygous frameshift 
mutation of GNRH1 has been previously described (Chan et al, PNAS 2009) with both parents being 
heterozygous.  
Supplemental Figure 1. 
 
Supplemental figure 1. Bioinformatics workflow for filtering and prioritization of CHH candidate 
genes.  
Supplemental Figure 2. 
 
Supplemental figure2. A. Relative expression of DCC RNA after transient transfection in CHO cells. B. 
Relative expression of Netrin-1 RNA after transient transfection in CHO cells. D. Dose-response curve 
with increasing quantity of Netrin-1 WT transfected in CHO cells. Results are mean of 3 independent 
experiments each performed in triplicate. Error bars represent SEM. 
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Supplemental Figure 3. 
 
Supplemental figure3. Full blot image of Figure 2. A-B, MW: Prism Ultra Protein Ladder (10-245 kDa) 
(Abcam, ab116028). 
 
  
Supplemental Figure 4. 
 
Representative of immunocytofluoresence of DCC in GN11 cells. GN11 cells are transfected with GFP 
or DCC plasmid, 24 hours post-transfection cells are plated onto poly-lysine coated coverslips for 24 
hours. Cells are stained for DCC (green), phalloïdin (red), noyau (blue).  
 
